Alumis (ALMS) Depreciation & Amortization (CF) (2023 - 2025)
Alumis (ALMS) posted quarterly Depreciation & Amortization (CF) of $867000.0 for Q4 2025, up 5.73% year-over-year from $820000.0 in Q4 2024, and down 5.35% quarter-over-quarter from $916000.0 in Q3 2025.
Powered by 
Analysis
Alumis (ALMS) Depreciation & Amortization (CF) (2023 - 2025) Analysis & Trends
Alumis (ALMS) has reported Depreciation & Amortization (CF) for 3 consecutive years, with $867000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) rose 5.73% year-over-year to $867000.0; the TTM figure through Dec 2025 stood at $3.5 million (up 10.91% YoY), while the FY2025 annual figure was $3.5 million, up 10.91% from the prior year.
- Depreciation & Amortization (CF) eased to $867000.0 in Q4 2025 per ALMS's latest filing, from $916000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $916000.0 in Q3 2025 and bottomed at $318000.0 in Q3 2023.
- Historically, Depreciation & Amortization (CF) has averaged $769200.0 across 3 years, with a median of $817000.0 in 2024.
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) jumped 155.97% — and 2025, when it rose 5.73%.
- Alumis' Depreciation & Amortization (CF) stood at $726000.0 in 2023, then gained by 12.95% to $820000.0 in 2024, then grew by 5.73% to $867000.0 in 2025.
- Business Quant data shows ALMS's Depreciation & Amortization (CF) at $867000.0 in Q4 2025, $916000.0 in Q3 2025, and $870000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | Alumis | 1.42 Bn | 917.08 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 867,000.00 |
| Sep 30, 2025 | 916,000.00 |
| Jun 30, 2025 | 870,000.00 |
| Mar 31, 2025 | 843,000.00 |
| Dec 31, 2024 | 820,000.00 |
| Sep 30, 2024 | 814,000.00 |
| Jun 30, 2024 | 760,000.00 |
| Mar 31, 2024 | 758,000.00 |
| Dec 31, 2023 | 726,000.00 |
| Sep 30, 2023 | 318,000.00 |